Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 42 current clinical trials in our China register. 28 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Irinotecan Hydrochloride Liposome, Letermovir and Peg-IFNα-2b. The most-studied condition is Coronary Artery Disease.

ClinicalTrials.gov trials by status

Recruiting2867%
Not yet open1126%
Active, closed25%
By invitation12%

Trials by phase

Observational2150%
Not applicable1331%
Phase EARLY_PHASE137%
Phase 325%
Phase 425%
Phase 212%

Clinical trials sponsored by First Affiliated Hospital Xi'an Jiaotong University

42 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery NCT06199401 · ClinicalTrials.gov ↗ · Type A Aortic Dissection, Complication of Surgical Procedure, Aortic Diseases	Not applicable	Recruiting	2024-01	China
Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance NCT06684106 · ClinicalTrials.gov ↗ · Hyperlipidemia, Ursodeoxycholic Acid, Statin Therapy	Not applicable	Recruiting	2024-11	China
Intravascular Ultrasound-Guided PCI in Patients With Chronic Kidney Disease NCT06567938 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Chronic Kidney Diseases	Not applicable	Recruiting	2024-07	China
Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting NCT06141525 · ClinicalTrials.gov ↗ · Coronary Artery Bypass Grafting, Remote Ischemic Conditioning, Ischemia-Reperfusion Injury	Not applicable	Recruiting	2023-11	China
Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics NCT06001073 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Arrhythmias, Cardiac, Heart Valve Diseases	Observational	Recruiting	2022-12	China
Risk Stratification Value of Biomarkers in Patients With Myocarditis NCT06010199 · ClinicalTrials.gov ↗ · Myocarditis	Observational	Recruiting	2023-08	China
Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis NCT06775782 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke	Not applicable	Recruiting	2025-08	China
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC NCT07796113 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2025-10	China
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia NCT06125847 · ClinicalTrials.gov ↗ · Homozygous Familial Hypercholesterolemia	Phase EARLY_PHASE1	Recruiting	2023-10	China
Prognosis of Heart Transplanted Patients With Heart Failure NCT05775432 · ClinicalTrials.gov ↗ · Heart Failure	Observational	Recruiting	2023-04	China
Peripheral Blood Lipidomic and Ceramide Profiles in Atrial Fibrillation NCT07757282 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF)	Observational	Recruiting	2017-06	China
Evaluation and Prediction of the Effect of EECP on HR-NICE Patients NCT05718622 · ClinicalTrials.gov ↗ · Stroke, Ischemic	Not applicable	Recruiting	2022-11	China
Magnetic Resonance Imaging Study on Young and Middle-aged Patients With Cervical Spondylotic Pain NCT06217029 · ClinicalTrials.gov ↗ · Neck Pain	Observational	Recruiting	2024-01	China
Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR） NCT05965362 · ClinicalTrials.gov ↗ · Infective Endocarditis	Observational	Recruiting	2024-05	China
Clinical Characteristics and Prognosis of Aortic Dissection in China (CLASSIC) NCT05999188 · ClinicalTrials.gov ↗ · Aortic Dissection	Observational	Recruiting	2023-10	China
Registry Study for Optimal Management of Liver Failure in the Chinese Population NCT05740696 · ClinicalTrials.gov ↗ · Liver Failure	Observational	Recruiting	2023-01	China
Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) NCT07389460 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke Drug: RhPro-UK	Phase 3	Recruiting	2026-04	China
Cohort Study of Clinical and Neuroimaging Characteristics for BPPV Patients in China NCT06228196 · ClinicalTrials.gov ↗ · BPPV, Vertigo, Vertigo, Peripheral	Observational	Recruiting	2024-01	China
Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine NCT07170176 · ClinicalTrials.gov ↗ · Migraine Disorders, Patent Foramen Ovale, Right-to-Left Shunt, Cardiac	Not applicable	Recruiting	2026-01	China
99mTc-P137 SPECT/CT in Prostate Cancer NCT05672485 · ClinicalTrials.gov ↗ · Prostate Cancer	Not applicable	Recruiting	2023-01	China
Evaluation of the Castor Single Branch Stent Graft in Treatment of Acute Aortic Syndrome NCT05965453 · ClinicalTrials.gov ↗ · Acute Aortic Syndrome	Observational	Recruiting	2018-06	China
Characteristics of Cardiac Tumor and the Risk Stratification of Subsequent Adverse Events (UNIQUE) NCT06100328 · ClinicalTrials.gov ↗ · Cardiac Tumor	Observational	Recruiting	2023-10	China
Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH） NCT06352320 · ClinicalTrials.gov ↗ · Cardiomyopathies	Observational	Recruiting	2024-05	China
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients NCT07266467 · ClinicalTrials.gov ↗ · Kidney Transplant Drug: Letermovir	Phase 4	Recruiting	2025-05	China
Effects of Remote Ischemic Preconditioning on Peripheral Blood Biomarkers in Healthy Adults (EMINENT) NCT05957523 · ClinicalTrials.gov ↗ · Ischemic Preconditioning	Not applicable	Recruiting	2024-06	China
Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy NCT06352307 · ClinicalTrials.gov ↗ · Arrhythmogenic Cardiomyopathy	Observational	Recruiting	2024-04	China
Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL). NCT07503730 · ClinicalTrials.gov ↗ · APL	Phase 3	Recruiting	2025-06	China
Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study NCT07079150 · ClinicalTrials.gov ↗ · Hepatitis B, Chronic (CHB), Hepatitis B, Hepatitis B Virus (HBV) Drug: Peg-IFNα-2b	Observational	Recruiting	2025-01	China
Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias NCT05965375 · ClinicalTrials.gov ↗ · Ventricular Arrythmia	Observational	Not yet open	2024-12	China
Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma NCT05681403 · ClinicalTrials.gov ↗ · Lymphoma, Autologous Hematopoietic Stem Cell Transplantation	Not applicable	Not yet open	2023-01	China
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma NCT07168291 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma	Phase EARLY_PHASE1	Not yet open	2025-12	China
Deep Learning for Intelligent Identification of Arrhythmias NCT05967546 · ClinicalTrials.gov ↗ · Arrhythmia	Observational	Not yet open	2024-12	China
Neoadjuvant PDT in the Treatment of Cholangiocarcinoma NCT04824742 · ClinicalTrials.gov ↗ · Cholangiocarcinoma Resectable	Not applicable	Not yet open	2021-04	China
Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder NCT06763237 · ClinicalTrials.gov ↗ · Autism Spectrum Disorder, Autism in Children	Not applicable	Not yet open	2025-01	China
Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer NCT06499610 · ClinicalTrials.gov ↗ · Gastric Cancer Drug: Irinotecan Hydrochloride Liposome	Phase 4	Not yet open	2024-07	China
Risk Stratification and Early Prevention Strategies for Non-compaction of Ventricular Myocardium (CAPTAIN) NCT06504056 · ClinicalTrials.gov ↗ · Isolated Noncompaction of the Ventricular Myocardium	Observational	Not yet open	2024-10	China
Hypotension Prediction Index and Intraoperative Hypotension Incidence NCT06909786 · ClinicalTrials.gov ↗ · Intraoperative Hypotension	Not applicable	Not yet open	2025-04	China
Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS) NCT06141538 · ClinicalTrials.gov ↗ · Atrial Fibrillation, Intracardiac Thrombus	Observational	Not yet open	2024-12	China
Acute Cerebrovascular Events in Patients Undergoing Catheter Ablation NCT05694273 · ClinicalTrials.gov ↗ · Arrhythmia, Acute Cerebrovascular Disease	Observational	Not yet open	2025-01	China
Randomized Controlled Study on the Safety and Efficacy of Phage Cocktail in the Treatment of Multidrug-Resistant Bacterial Skin Infections NCT07619924 · ClinicalTrials.gov ↗ · Phage Therapy, Bacteriophage Therapy, Skin and Soft Tissue Infections	Phase EARLY_PHASE1	By invitation	2025-01	China
To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse NCT07730619 · ClinicalTrials.gov ↗ · Plaque Psoriasis, Biologic Agents, Relapse	Observational	Active, closed	2022-12	China
Establishment of a Model for Predicting the Prognosis of HBV-related Decompensated Liver Cirrhosis Based on RFH-NPT NCT05513651 · ClinicalTrials.gov ↗ · Liver Cirrhosis, Malnutrition	Observational	Active, closed	2016-07	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in First Affiliated Hospital Xi'an Jiaotong University trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Irinotecan Hydrochloride Liposome1 Letermovir1 Peg-IFNα-2b1 RhPro-UK1

Conditions in First Affiliated Hospital Xi'an Jiaotong University trials

67 conditions

Coronary Artery Disease2 Aortic Dissection2 Acute Ischemic Stroke2Arrhythmia2Type A Aortic Dissection1Complication of Surgical Procedure1Aortic Diseases1Ventricular Arrythmia1Hyperlipidemia1Ursodeoxycholic Acid1Statin Therapy1Glucose Intolerance1Chronic Kidney Diseases1 Coronary Artery Bypass Grafting1Remote Ischemic Conditioning1Ischemia-Reperfusion Injury1Arrhythmias, Cardiac1Heart Valve Diseases1Myocarditis1Lymphoma1Autologous Hematopoietic Stem Cell Transplantation1Diffuse Large B Cell Lymphoma (DLBCL)1 Follicular Lymphoma ( FL)1Burkitt Lymphoma1

By trial register

Register	Trials	Recruiting
Clinical trials in China	42	28

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Coronary Artery Disease

Sponsor	Trials
China National Center for Cardiovascular Diseases	12
Nanjing First Hospital, Nanjing Medical University	10
Second Affiliated Hospital, Zhejiang University, School of Medicine	8
Shanghai Zhongshan Hospital	7
Xijing Hospital	6
Seung-Jung Park	3
Second Hospital of Jilin University	3
National University of Ireland, Galway, Ireland	2
Philips Clinical & Medical Affairs Global	2
Biosensors Europe	2

Sponsors with the most current trials registered for this condition.

Questions about First Affiliated Hospital Xi'an Jiaotong University trials

How many clinical trials does First Affiliated Hospital Xi'an Jiaotong University sponsor?

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 42 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are First Affiliated Hospital Xi'an Jiaotong University trials recruiting?

Yes. 28 of its 42 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is First Affiliated Hospital Xi'an Jiaotong University testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Irinotecan Hydrochloride Liposome (1), Letermovir (1), Peg-IFNα-2b (1) and RhPro-UK (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

First Affiliated Hospital Xi'an Jiaotong University clinical trials